ALN-5288 (MAPT) Overview

An Investigational RNAi Therapeutic

Disease State(s) Under Investigation	Alzheimer's disease[1]
MoA	Designed to target production of microtubule-associated protein Tau (MAPT)[2]
Route of Administration	Intrathecal[1]

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Recruiting		
Safety, Tolerability, PK, and PD of **ALN-5288** Adult Patients With Alzheimer's Disease[1]	ALN-5288; placebo	Safety (frequency and severity of AEs up to 32 months)

The ALN-5288 clinical program is being conducted in partnership with Regeneron

The safety and efficacy of ALN-5288 has not been established by any health authority.

AE, adverse event; MAPT, microtubule associated protein Tau; MoA, mechanism of action; PD, pharmacodynamics; PK, pharmacokinetics; RNA, ribonucleic acid; RNAi, RNA interference. 1. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07214727 (Accessed May 4, 2026). 2. Alnylam Pharmaceuticals, Inc. 2025. https://investors.alnylam.com/press-release?id=29381 (Accessed February 17, 2026).

Alnylam